For fiscal 2025 (ended Dec 31, 2025), Cellebrite DI Ltd. reported $475.68M of revenue and $78.33M of net income.
CLBT revenue was $475.68M for fiscal 2025 (ended Dec 31, 2025), up 18.6% from fiscal 2024. Compound annual growth was +19.5% over 5 years. It rose in each of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.
CLBT net income was $78.33M for fiscal 2025 (ended Dec 31, 2025), compared with -$283.01M in fiscal 2024. Compound annual growth was +68.4% over 5 years.
CLBT diluted EPS was $0.31 for fiscal 2025 (ended Dec 31, 2025), compared with -$1.35 in fiscal 2024.
CLBT free cash flow was $160.32M for fiscal 2025 (ended Dec 31, 2025), up 29.7% from fiscal 2024. Compound annual growth was +21.6% over 5 years. It rose in 4 of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $475.68M | $401.20M | $325.11M | $270.65M | $246.25M | $194.91M | $171.85M |
| Cost of revenue | $75.17M | $62.59M | $53.23M | $50.75M | $42.56M | $37.88M | $35.82M |
| Gross profit | $400.50M | $338.61M | $271.88M | $219.91M | $203.69M | $157.03M | $136.03M |
| Research and development | $113.88M | $98.42M | $84.39M | $80.62M | $65.54M | $54.38M | $46.57M |
| Selling, general and admin | $65.33M | $50.90M | $43.44M | $40.85M | $47.94M | $32.13M | $29.37M |
| Operating income | $66.48M | $56.91M | $33.24M | $1.04M | $13.82M | $9.22M | -$1.52M |
| Pre-tax income | $90.68M | -$275.98M | -$75.56M | $120.76M | $82.31M | $11.40M | $1.42M |
| Income tax | $12.35M | $7.02M | $5.54M | -$45.0K | $10.91M | $5.62M | $3.29M |
| Net income | $78.33M | -$283.01M | -$81.10M | $120.81M | $71.40M | $5.78M | -$1.88M |
| EPS, basic | $0.32 | -$1.35 | -$0.43 | $0.64 | $0.49 | -$0.08 | -$0.08 |
| EPS, diluted | $0.31 | -$1.35 | -$0.43 | $0.59 | $0.44 | -$0.08 | -$0.08 |
| Diluted shares | 249.9M | 209.5M | 190.2M | 195.4M | 161.5M | 123.7M | 121.6M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $124.46M | $191.66M | $189.52M | $87.64M | $145.97M | $133.85M | $81.68M |
| Short-term investments | $151.54M | $101.82M | $38.69M | $44.64M | $0 | - | - |
| Receivables | $104.97M | $82.36M | $77.27M | $78.76M | $67.50M | $66.32M | - |
| Inventory | $7.60M | $8.94M | $9.94M | $10.18M | $6.51M | $4.75M | - |
| Current assets | $575.85M | $567.59M | $422.08M | $295.93M | $273.21M | $324.27M | - |
| Goodwill | $119.56M | $28.71M | $26.83M | $26.83M | $26.83M | $9.46M | - |
| Total assets | $938.85M | $690.57M | $532.88M | $403.29M | $339.78M | $364.39M | - |
| Current liabilities | $369.66M | $295.50M | $253.82M | $207.78M | $186.57M | $159.38M | - |
| Total liabilities | $454.53M | $354.55M | $498.67M | $329.43M | $413.13M | $199.38M | - |
| Shareholders' equity | $484.32M | $336.02M | $34.21M | $73.86M | -$73.35M | $63.80M | $58.83M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $173.54M | $132.17M | $102.06M | $20.58M | $36.05M | $66.51M | $16.13M |
| Capital expenditures | $13.22M | $8.57M | $5.23M | $6.90M | $5.11M | $6.18M | $6.21M |
| Free cash flow | $160.32M | $123.61M | $96.83M | $13.68M | $30.94M | $60.33M | $9.92M |
| Investing cash flow | -$268.25M | -$149.47M | -$22.54M | -$91.23M | $45.23M | -$6.45M | -$46.72M |
| Financing cash flow | $25.05M | $20.65M | $21.77M | $13.97M | -$68.40M | -$8.59M | $75.54M |
| Dividends paid | - | - | $0 | $0 | $100.00M | $10.00M | $25.00M |
| Share repurchases | - | - | - | $0 | $0 | $85.0K | $808.0K |
| Stock-based compensation | $44.89M | $30.57M | $19.00M | $13.71M | $6.48M | $7.27M | $12.76M |
| Depreciation and amortization | $11.87M | $10.61M | $10.01M | $9.19M | $7.01M | $5.88M | $4.08M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 18.6% | 23.4% | 20.1% | 9.9% | 26.3% | 13.4% | - |
| Net income growth, YoY | - | - | - | 69.2% | 1135.0% | - | - |
| EPS growth, YoY | - | - | - | 34.1% | - | - | - |
| Gross margin | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% | 80.6% | 79.2% |
| Operating margin | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% | 4.7% | -0.9% |
| Net margin | 16.5% | -70.5% | -24.9% | 44.6% | 29.0% | 3.0% | -1.1% |
| Free cash flow margin | 33.7% | 30.8% | 29.8% | 5.1% | 12.6% | 31.0% | 5.8% |
| Return on equity | 16.2% | -84.2% | -237.1% | 163.5% | - | 9.1% | -3.2% |
| Return on assets | 8.3% | -41.0% | -15.2% | 30.0% | 21.0% | 1.6% | - |
| Current ratio | 1.56 | 1.92 | 1.66 | 1.42 | 1.46 | 2.03 | - |
Source: XBRL data Cellebrite DI Ltd. files with the SEC, latest filing dated Mar 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CLBT | $475.68M | +18.6% | $78.33M | 16.5% | $3.18B |
| MSFT | $346.44B | +17.9% | $142.63B | 41.2% | $3.96T |
| PLTR | $7.29B | +87.1% | $3.67B | 50.3% | $406.77B |
| ORCL | $71.78B | +21.6% | $18.92B | 26.4% | $356.74B |
| SAP | €36.80B | +7.7% | €7.16B | 19.5% | $287.15B |
| CRWD | $5.40B | +24.3% | $58.46M | 1.1% | $231.16B |
| SHOP | $14.17B | +32.5% | $2.13B | 15.0% | $188.62B |
| CRM | $43.94B | +11.2% | $9.66B | 22.0% | $175.69B |
| NET | $2.73B | +35.7% | -$239.05M | -8.7% | $109.59B |